Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to document the progression free survival (PFS) in
advanced or metastatic colorectal cancer patients treated with NGR-hTNF as single agent.
Safety will be established by clinical and laboratory assessment according to NCI-CTC
criteria.